Source: Contract Pharma

Alzprotect: AlzProtect & PAREXEL Biotech Enter Collaboration

For the performance of the clinical phase 2a development of AZP2006 for the treatment of PSP, a rare degenerative disease of the brain

Read full article »
Alzprotect's Competitors | Alzprotect's News | Alzprotect's Financials
Stay up-to-date with the latest news on Alzprotect
Est. Annual Revenue
$100K-5.0M
Est. Employees
1-25
Philippe Verwaerde's photo - CEO of Alzprotect

CEO

Philippe Verwaerde

CEO Approval Rating

68/100

Read more
Stay up-to-date with the latest news on Alzprotect